News & Views | Published:

Vasculitis syndromes: Tocilizumab — a new frontier for GCA therapy

Nature Reviews Rheumatology volume 13, pages 700701 (2017) | Download Citation

An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed or relapsing GCA, is changing the landscape of treatment and ushering in a new era of biologic therapy.

  • Subscribe to Nature Reviews Rheumatology for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56, 2789–2797 (2007).

  2. 2.

    et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).

  3. 3.

    et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase II, randomised, double-blind, placebo-controlled trial. Lancet 387, 1921–1927 (2016).

  4. 4.

    , & Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr. Opin. Rheumatol 28, 211–217 (2016).

  5. 5.

    et al. Newly diagnosed versus relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin. Arthritis Rheum. 46, 657–664 (2017).

  6. 6.

    et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. (Hoboken) 64, 1720–1729 (2012).

  7. 7.

    et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann. Rheum. Dis. 73, 1826–1832 (2014).

  8. 8.

    et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod. Pathol. 30, 788–796 (2017).

  9. 9.

    & Immune mechanisms in medium and large-vessel vasculitis. Nat. Rev. Rheumatol 9, 731–740 (2013).

  10. 10.

    et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 69, 837–845 (2017).

Download references

Author information

Affiliations

  1. Matthew J. Koster and Kenneth J. Warrington are at Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.

    • Matthew J. Koster
    •  & Kenneth J. Warrington

Authors

  1. Search for Matthew J. Koster in:

  2. Search for Kenneth J. Warrington in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Kenneth J. Warrington.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2017.150

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.